Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The purinergic P2X7 receptor (P2X7R), an ATP-gated non-selective cation channel, has emerged as a gatekeeper of inflammation that controls the release of proinflammatory cytokines. As a key player in initiating the inflammatory signaling cascade, the P2X7 receptor is currently under intense scrutiny as a target for the treatment of different pathologies, including chronic inflammatory disorders (rheumatoid arthritis and osteoarthritis), chronic neuropathic pain, mood disorders (depression and anxiety), neurodegenerative diseases, ischemia, cancer (leukemia), and many others. For these reasons, pharmaceutical companies have invested in discovering compounds able to modulate the P2X7R and filed many patent applications. This review article presents an account of P2X7R structure, function, and tissue distribution, emphasizing its role in inflammation. Next, we illustrate the different chemical classes of non-competitive P2X7R antagonists reported by highlighting their properties and qualities as clinical candidates for treating inflammatory disorders and neurodegenerative diseases. We also discuss the efforts to develop effective Positron Emission Tomography (PET) radioligands to progress the understanding of the pathomechanisms of neurodegenerative disorders, to provide evidence of drug-target engagement, and to assist clinical dose selection for novel drug therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - 31(2024), 11 vom: 20., Seite 1361-1403 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Idrissi, Imane Ghafir [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 01.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/0929867330666230403094538 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355182033 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355182033 | ||
| 003 | DE-627 | ||
| 005 | 20240201231852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0929867330666230403094538 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM355182033 | ||
| 035 | |a (NLM)37013427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Idrissi, Imane Ghafir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The purinergic P2X7 receptor (P2X7R), an ATP-gated non-selective cation channel, has emerged as a gatekeeper of inflammation that controls the release of proinflammatory cytokines. As a key player in initiating the inflammatory signaling cascade, the P2X7 receptor is currently under intense scrutiny as a target for the treatment of different pathologies, including chronic inflammatory disorders (rheumatoid arthritis and osteoarthritis), chronic neuropathic pain, mood disorders (depression and anxiety), neurodegenerative diseases, ischemia, cancer (leukemia), and many others. For these reasons, pharmaceutical companies have invested in discovering compounds able to modulate the P2X7R and filed many patent applications. This review article presents an account of P2X7R structure, function, and tissue distribution, emphasizing its role in inflammation. Next, we illustrate the different chemical classes of non-competitive P2X7R antagonists reported by highlighting their properties and qualities as clinical candidates for treating inflammatory disorders and neurodegenerative diseases. We also discuss the efforts to develop effective Positron Emission Tomography (PET) radioligands to progress the understanding of the pathomechanisms of neurodegenerative disorders, to provide evidence of drug-target engagement, and to assist clinical dose selection for novel drug therapies | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Purinergic P2X7 receptor | |
| 650 | 4 | |a antagonists | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a neurodegenerative disorders | |
| 650 | 4 | |a positron emission tomography. | |
| 650 | 7 | |a Purinergic P2X Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Receptors, Purinergic P2X7 |2 NLM | |
| 700 | 1 | |a Podlewska, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Abate, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Bojarski, Andrzej J |e verfasserin |4 aut | |
| 700 | 1 | |a Lacivita, Enza |e verfasserin |4 aut | |
| 700 | 1 | |a Leopoldo, Marcello |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g 31(2024), 11 vom: 20., Seite 1361-1403 |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:11 |g day:20 |g pages:1361-1403 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0929867330666230403094538 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 11 |b 20 |h 1361-1403 | ||